Table 1.

Association of genes with clinical outcome in breast cancer patients treated with and without anthracycline chemotherapya

GenesCohort 1b HR (95% CI)Cohort 2c AUC (95% CI)
IFN-γ0.8 (0.65–0.95), P = 0.0310.69 (0.56–0.81), P = 0.016
CD8A0.82 (0.5–1.3), P = 0.40.72 (0.59–0.84), P = 0.005
CD8B0.87 (0.59–1.3), P = 0.210.65 (0.52–0.78), P = 0.049
IL17A0.82 (0.67–1.1), P = 0.0510.5, P = 0.44
IL1B0.87 (0.7–1.06), P = 0.180.39, P = 0.19
IL230.88 (0.75–1.03), P = 0.130.56, P = 0.42

Abbreviation: pCR, pathologic complete response.

  • aAssociation of genes with clinical outcome in breast cancer patients treated with and without anthracycline chemotherapy. Cohort 1 consisted of 1,062 patients from 4 gene expression data sets who received no systemic treatment after their surgery to determine the clinical outcome association independent of anthracycline. Seventy percent of tumors were ER-positive, 85% were node negative at diagnosis. Univariate HRs presented are stratified by data set. Genes are correlated as continuous variables. Here, increasing expression of IFN-γ is correlated with a good prognosis or a longer time free from distant metastases. Cohort 2 consisted of 114 patients treated in a neoadjuvant trial of the anthracycline epirubicin given as a sole therapy prior to surgery. All patients were ER-negative with 86% of tumors greater than 2 cm and 54% with positive lymph nodes at study entry. Biopsies were taken prior to therapy. Here, increasing expression of IFN-γ, CD8A, and CD8B is associated with a higher chance of a complete response from chemotherapy at surgery. In this second cohort, a pCR was strongly correlated with a better survival from breast cancer. (Full clinical information for cohorts 1 and 2 can be found in the Supplementary Table S1.)

  • bEndpoint: distant metastases; number of patients = 1,062; treatment = none.

  • cEndpoint: pCR (complete disappearance of invasive tumor at surgery after 4 cycles of epirubicin chemotherapy given at 100 mg/m2); number of patients = 114; treatment = epirubicin monotherapy.